Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22142221 | 1.00 | ALDH1A1 (0.36) | ALDH1A1L3MBTL1SIGMAR1HTTHRH3 | |
| SCHEMBL22142226 | 1.00 | ALDH1A1 (0.36) | ALDH1A1L3MBTL1SIGMAR1HTTHRH3 | |
| SCHEMBL22142133 | 1.00 | ALDH1A1 (0.36) | ALDH1A1L3MBTL1SIGMAR1HTTHRH3 | |
| SCHEMBL8442153 | 1.00 | ALDH1A1 (0.36) | ALDH1A1L3MBTL1SIGMAR1HTTHRH3 | |
| SCHEMBL17354466 | 0.91 | ALDH1A1 (0.33) | ALDH1A1SIGMAR1 | |
| SCHEMBL22142300 | 0.85 | — | — | |
| SCHEMBL22142389 | 0.85 | — | — | |
| SCHEMBL17809024 | 0.85 | — | — | |
| SCHEMBL22142184 | 0.85 | — | — | |
| SCHEMBL17693485 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | CELGENE CORPORATION (US) | 2021-11-09 | — | — | US | disclosed |
| WO-2020132384-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | CELGENE CORPORATION (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | CELGENE CORPORATION | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | ALDH1A1 4498/4885L3MBTL1 3299/4885SIGMAR1 3836/4885 |
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | RIPK2, RIPK1, RIPK4 | ALDH1A1 4498/4885L3MBTL1 3299/4885SIGMAR1 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.